Close menu




June 28th, 2021 | 11:15 CEST

Pfizer, Sartorius, Defence Therapeutics: Health as an investment opportunity

  • Biotechnology
Photo credits: pixabay.com

Tremendous opportunities lie dormant in biotech companies. New therapeutic approaches are suitable for fighting civilization diseases such as cardiovascular problems, cancer and Alzheimer's. In recent years, there has been a whole series of scientific breakthroughs. Some studies have shown phenomenal possibilities. It is now up to innovative companies to turn laboratory findings into practical clinical results. For shareholders, the opportunities are plentiful.

time to read: 3 minutes | Author: Nico Popp
ISIN: PFIZER INC. DL-_05 | US7170811035 , SARTORIUS AG O.N. | DE0007165607 , DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Pfizer: Better to invest in big brother?

    The fact that biotech companies are on the verge of finding a holy grail in many areas is something that even the big pharmaceutical multinationals, such as Pfizer, are aware of. Not for nothing did the US Company enter into a partnership with the German Company BioNTech early on when it came to mRNA vaccines. But Pfizer also shines in other areas: last year, sales of cancer drugs went up. Rare disease drugs also contributed to the strong results, generating 30% sales growth on their own. Although some former box-office hits, such as the drugs Lipitor and Norvasc, weakened in 2020, the overwhelming success of BioNTech and its vaccine should compensate for this in the current year.

    Pfizer is making money with every dose. It is now clear that BioNTech is even a little better than AstraZeneca's product, which is also very good. It protects against the new virus variants and is therefore likely to remain on the shopping lists of countries and companies for some time to come. When it comes to renewing existing vaccine doses, BioNTech/Pfizer is also likely to have a strong position with customers. The share is extremely solid and should also have potential in the medium and long term.

    Sartorius: The pandemic stock par excellence

    One Company that quickly emerged as a winner in the pandemic is Sartorius. The specialist for disposables, laboratory instruments and consumables is the Corona stock par excellence. You do not need to look at the annual report to see that. The frequency with which we have all come into contact with Coronatests and other side effects of the pandemic in recent months alone proves the relevance of the Company from Göttingen.

    In 2020, Sartorius' total sales revenue climbed a whopping 20%. Order intake even rose by more than 40%. Even though the pandemic currently seems to be under control, vaccination rates below 80% are likely to cause one or the other stutter in the economy and everyday life again in the fall - Sartorius products will continue to be needed. After the rally of the first wave, the share price has turned sideways a little. However, the fundamental direction is positive.

    Defence Therapeutics: Vaccines against cancer become more likely

    Unlike Pfizer and Sartorius, one Company that is not yet familiar to every market participant is Defence Therapeutics. The Company has developed its patented Accum™ technology designed to deliver active ingredients precisely to the source of infections or diseases. The technology can "piggyback" on specific agents using antibodies. These antibodies block a receptor at the affected site and guide the active ingredient into the cell. Accum™ specifically ensures that the antibody used is equipped with an amino acid chain that increases the cell nucleus concentration of the respective active ingredient, thus making it easier for it to enter the affected cells. As a second mainstay, Defence Therapeutics develops vaccines and a few weeks ago announced promising results of the vaccine AccuVAC-D001 in the treatment of mice suffering from cancer. The pre-clinical study showed that 70% of cases in mice with established solid tumors were cured.

    Now, mice are not humans, and a pre-clinical study is not yet a breakthrough in the fight against cancer. But the results show that Defence Therapeutics is making promising progress around one of humanity's worst diseases. The Accum™ technology can be considered promising. Using partially aggressive drugs in a targeted manner can reduce side effects and possibly make certain forms of treatment worthwhile in the first place. The share price has already risen in recent weeks and is currently consolidating. Investors should take a closer look at Defence Therapeutics.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.

    Read

    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.

    Read

    Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST

    Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa

    • Mining
    • Gold
    • Commodities
    • Biotechnology
    • airline

    The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!

    Read